HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Aims to achieve CDMO sales of US$ 400 million by 2028
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Subscribe To Our Newsletter & Stay Updated
